Home › NDC Lookup › RxCUI directory › RxCUI 2731482

Aficamten 5 MG Oral Tablet — RxCUI 2731482

RxNorm drug concept · Semantic clinical drug
RxCUI 2731482 Semantic clinical drug · SCD ● Current RxNorm concept 4 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2731482
Official nameAficamten 5 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped4
Package NDCs mapped4
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Aficamten: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Myqorzo targets the root cause of your symptoms. In obstructive HCM, the heart muscle is overactive — it squeezes too hard, thickens, and creates a blockage that limits blood flow...
  • What is Myqorzo actually doing for my heart condition?
  • Because Myqorzo works by reducing the heart's pumping force, it can — in some people — reduce the ejection fraction (how much blood the heart pumps out each beat) too much, which c...
  • Why do I need echocardiograms so often while taking this medication?
📖 Read our full Aficamten guide →

🕸️ Concept Web — How Aficamten 5 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Aficamten 5 MG Oral Tablet RxCUI 2731482

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Aficamten 2731469
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Myqorzo 2731475
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Aficamten Oral Tablet 2731473
    • Aficamten Oral Product 2731471
    • Aficamten Pill 2731472
    • Aficamten Oral Tablet [Myqorzo] 2731479
    • Myqorzo Oral Product 2731477
    • Myqorzo Pill 2731478
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Aficamten 5 MG SCDC · 2731481
  • Aficamten Oral Tablet SCDF · 2731473
  • Aficamten Oral Product SCDG · 2731471
  • Aficamten Pill SCDG · 2731472

Brand-Name Concepts

  • Aficamten 5 MG Oral Tablet [Myqorzo] SBD · 2731484
  • Aficamten 5 MG [Myqorzo] SBDC · 2731483
  • Aficamten Oral Tablet [Myqorzo] SBDF · 2731479
  • Myqorzo Oral Product SBDG · 2731477
  • Myqorzo Pill SBDG · 2731478
  • Myqorzo BN · 2731475

📦 FDA Products & Package NDCs

4 products · 4 package NDCs
4 package NDCs map to RxCUI 2731482 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
82112-0105-30 30 TABLET, FILM COATED in 1 BOTTLE (82112-105-30) MYQORZO Cytokinetics Inc. 2026-01-12
82112-0110-30 30 TABLET, FILM COATED in 1 BOTTLE (82112-110-30) MYQORZO Cytokinetics Inc. 2026-01-12
82112-0115-30 30 TABLET, FILM COATED in 1 BOTTLE (82112-115-30) MYQORZO Cytokinetics Inc. 2026-01-12
82112-0120-30 30 TABLET, FILM COATED in 1 BOTTLE (82112-120-30) MYQORZO Cytokinetics Inc. 2026-01-12
Observed labelers: Cytokinetics Inc. (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.